Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks
08 juin 2017 16h10 HE
|
Adamas Pharmaceuticals, Inc.
-- New subgroup analyses showed that patients previously treated with amantadine IR received benefit of ADS-5102 comparable to patients previously treated with placebo -- -- New Drug Application...
Adamas to Present at the 37th Annual Cowen Health Care Conference
01 mars 2017 14h43 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is...
Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements
08 janv. 2017 19h57 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today outlines key business priorities for 2017, in addition to providing a review of 2016...